Mr. David Judd, a consultant cellular
biologist, and Chief Executive Officer of Pharmacyte
Biotech Inc (OTCMKTS:PMCB)
, Kenneth L. Waggoner will visit the GMP production facility of
Austrianova in Bangkok, Thailand. They will oversee the production of a clinical
trial material to treat non-metastatic and locally advanced inoperable
pancreatic cancer. Judd and Wagonner will witness the culturing of genetically changed
HEK-293 cells before and after the encapsulation process.

Expertise of Judd

Judd has experience in developing cell culture media for
several cell lines and primary cells. He has knowledge in HEK-293 cells growth.
Judd’s credits include development of cell assays, manufacturing processes, downstream
recovery strategies, cell culture processes, and biochemical analysis.

The company has requested the on-site presence of Judd to
help correct any problems in the manufacturing process because the most recent two
staggered processes are already completed.

Waggoner said they are on track after incorporating changes
in the manufacturing process and proceed with CypCaps GMP production. He felt
that their presence is necessary at the site to oversee the entire process
during production of the clinical material for non-metastatic and locally
advanced inoperable pancreatic cancer. It ensures they are on the path and within
the time limit to submit IND (investigational new drug) application. Therefore,
the presence of Judd is an absolute necessity because the two manufacturing
processes are conducted in a staggered manner.

Interview in Thailand

There is a possibility to interview Austrianova’s Dr. Brian
Salmons, Prof. Dr. Walter H. Günzburg, Judd, and Waggoner on the progress of
production of clinical material for trial while in Bangkok. The interviewers
may ask details of the factors involved in the production process, and clinical
trial product testing in submitting IND.

Pharmacyte may post the interviews,
images, and videos on social media while CEO and Judd are on at the site. Interested
parties in the content can visit the social media platforms of the company.

Cannabinoid therapy for cancer

The University of Northern Colorado, the partner of
Pharmacyte, bioengineered the human cell line for activating cannabinoid pro
drug. The main aim is to develop a cannabinoid therapy to cure brain cancer. In
the next step, it will test the transfected cells efficiency in altering the
cannabinoid drugs into the active cancer treatment form.